News

Teva Pharmaceuticals has launched the first generic version of Perforomist (formoterol fumarate inhalation solution) for the treatment of chronic obstructive pulmonary disease (COPD) in the U.S. “Teva is pleased to provide patients with first-to-market access to a generic version of Perforomist,” Christine Baeder, senior vice president and…

Hospitalizations for chronic obstructive pulmonary disease (COPD) dropped by half after the implementation of public health measures to curb the spread of COVID-19 infections, according to a U.S. study. This reduction in COPD hospital admissions was 36% greater than “the declines seen in other serious medical conditions, including…

Glenmark Pharmaceuticals has launched Tiogiva, a tiotropium bromide dry powder inhaler (DPI) for the treatment of chronic obstructive pulmonary disease (COPD), in the U.K. Tiogiva is the bioequivalent generic version of Boehringer Ingelheim’s…

Although lung cancer development is unpredictable, patients with chronic obstructive pulmonary disease (COPD) appear more likely to have the cancer and a worse prognosis compared with the general population, a Japanese study has found. Annual computed tomography (CT) screens may help with the early detection and treatment of this…

TrialSpark, a technology company that helps streamline the clinical trial process, has partnered with global biopharmaceutical company Sanofi to conduct clinical studies and accelerate the development of new treatments for chronic obstructive pulmonary disease (COPD). TrialSpark’s system is expected to improve the enrollment of Black and Hispanic COPD…

Medical Mutual of Ohio now covers Spiration Valve System (SVS), Olympus‘ minimally invasive therapy for eligible patients with severe emphysema, a progressive form of chronic obstructive pulmonary disease (COPD). “This decision by Medical Mutual will provide expanded access to this critical therapy that significantly reduces lung hyperinflation associated with…

The National Heart, Lung, and Blood Institute awarded $962,000 to a University of Buffalo researcher to develop risk models that help to improve patient care and lower hospital readmission rates for people with chronic obstructive pulmonary disease (COPD). “Each year, 7.8 million hospital-discharged patients are readmitted, costing the United…

The Zephyr Endobronchial Valve significantly improved lung function and quality of life for at least two years in people with emphysema, a severe form of chronic obstructive pulmonary disease (COPD), according to new clinical trial data. “These long-term data further demonstrate that our Zephyr Valve is a safe,…

Approximately 40% of chronic obstructive pulmonary disease (COPD) patients in the U.S. — and notably, most of those living in small towns or rural areas — have limited access to pulmonary rehabilitation (PR) maintenance programs, according to a recent study. Indeed, roughly 17% of people with COPD from this…

Note: This story was updated May 21, 2021, as an earlier version of this article misidentified Renu Jain, PhD, scientific director of medical affairs at GlaxoSmithKline.  People with chronic obstructive pulmonary disease (COPD) who do not experience exacerbations, or flare-ups, within the previous 12 months are still at risk…